The federal Medicare program has announced its schedule for the third round of drug price negotiations, targeting 10 additional medications under the landmark Inflation Reduction Act provisions aimed at reducing healthcare costs for seniors.
The U.S. Medicare program revealed on Monday its comprehensive timeline for the third round of prescription drug price negotiations, continuing the implementation of the Biden administration’s landmark initiative to reduce medication costs for seniors and taxpayers.
This third phase will target 10 additional prescription medications, with final negotiated prices scheduled to be announced by September 1, 2026, before taking effect at the beginning of 2027.
Key Dates and Selection Process
According to the published timeline, Medicare will identify the 10 drugs selected for this negotiation round on February 1, 2026. Pharmaceutical manufacturers will then receive initial offers from the federal health program by June 1, 2026, setting the stage for the negotiation process.
The law authorizes Medicare, which provides health insurance for over 65 million elderly and disabled Americans, to select drugs for negotiation based on several criteria. Primary considerations include their total expenditure within the Medicare system and the length of time they have been on the market without generic or biosimilar competition.
This third round will focus specifically on drugs covered under Medicare Part D, which handles prescription medications that patients take at home.
Industry Response and Legal Challenges
The pharmaceutical industry has aggressively pushed back against the government’s price negotiation authority, with multiple companies and industry groups filing lawsuits challenging the constitutionality of the program.
“The negotiation process is nothing more than the government demanding an arbitrary price under the threat of an excise tax of up to 1,900% of sales,” said a spokesperson from the Pharmaceutical Research and Manufacturers of America (PhRMA), the industry’s primary trade group.
Despite these legal challenges, the federal government has continued moving forward with the program, which was established under the 2022 Inflation Reduction Act.
Previous Negotiation Rounds
The first round of negotiations addressed 10 drugs, resulting in price reductions averaging 46%, according to Medicare officials. These reduced prices are scheduled to take effect in January 2026.
The second round, currently in progress, includes 15 medications – 10 covered under Medicare Part D and five hospital-administered drugs under Medicare Part B. The list of drugs for this round was announced in August, with manufacturers having received initial price offers last month.
Final prices from the second negotiation round are expected to be published by August 2025 and will be implemented in January 2026, coinciding with the first round’s price changes.
Broader Impact on Healthcare Costs
The drug negotiation program represents a significant shift in U.S. healthcare policy, as Medicare previously lacked the authority to directly negotiate prices with pharmaceutical manufacturers.
The Biden administration has highlighted these negotiations as a cornerstone of its efforts to reduce healthcare costs for Americans, particularly seniors who often face significant medication expenses.
“For years, Medicare was banned from negotiating lower prescription drug prices while drug companies could raise prices seemingly without limit,” said a senior health official. “These negotiations are changing that dynamic and putting the health of people with Medicare ahead of pharmaceutical companies’ profits.”
According to government projections, the negotiation program is expected to save Medicare and its beneficiaries billions of dollars over the next decade, though actual savings will depend on the specific medications selected and the final negotiated prices.
Looking Forward
Future rounds of negotiation will continue addressing additional medications, with the law allowing Medicare to negotiate prices for up to 15 drugs in 2028 and 2029, and up to 20 drugs in subsequent years.
Healthcare policy experts note that the program’s impact will likely grow over time as more medications undergo the negotiation process and as the government refines its approach based on experience gained in these initial rounds.
Patient advocacy groups have generally supported the negotiations, highlighting the potential for reduced out-of-pocket costs for seniors, while continuing to monitor the program to ensure it doesn’t negatively impact medication access or pharmaceutical innovation.